New combo therapy aims to improve glucose control in type 1 diabetes
NCT ID NCT07087795
First seen Apr 19, 2026 · Last updated Jun 10, 2026 · Updated 13 times
Summary
This early-stage study is testing a new drug called NNC0194-0499 in 96 adults with type 1 diabetes. The goal is to see if it can improve blood sugar levels when used alone or with another diabetes drug (semaglutide), while everyone continues their standard insulin therapy. The study lasts about 36 weeks and focuses on safety and how well the drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Profil Institut für Stoffwechselforschung GmbH
Neuss, 41460, Germany
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.